Disclosure of Remuneration for Non-Audit Services

RNS Number : 9790C

MaxCyte, Inc.

22 October 2020

 

Disclosure of Remuneration for Non-Audit Services

Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an update to its previous disclosure of remuneration for audit-related services.

The Company previously disclosed on 14 October 2020 that the remuneration of the Company's auditors, Cohn Rezhnick LLC, for services relating to the 2019 financial year, amounted to approximately $137,000.

In order to further assist investors in considering the resolutions proposed ahead of the Company AGM, MaxCyte advises that these fees consisted of $119,000 for audit services and $18,000 for tax services, with no further costs incurred for any other services. 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit  www.maxcyte.com .

###

Contacts:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer	[phone]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden	[phone]
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh --------------------------------------------------------------	[phone] maxcyte@consilium-com

 

END

 

 

MSCKKBBBOBDDDKB